AGTC Announces Pricing of Public Offering of Common Stock

2 years ago

GAINESVILLE, Fla., and CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology…

Yield10 Bioscience to Present at the Maxim Group 2022 Virtual Growth Conference and Participate in Fireside Chat

2 years ago

WOBURN, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company,…

BioCorRx to Participate in Two Upcoming Conferences

2 years ago

ANAHEIM, CA, March 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of…

Psychemedics Corporation Welcomes Drew Reynolds to Its Board of Directors and Announces the Retirement of Harry Connick From His Director Role

2 years ago

ACTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs…

Integra LifeSciences Launches NeuraGen® 3D Nerve Guide Matrix

2 years ago

The Next Generation of Nerve Conduits NeuraGen 3D Nerve Guide Matrix NeuraGen 3D Guide Matrix, a resorbable implant for the…

Sharps Compliance Announces New $36.0 Million Credit Facility

2 years ago

HOUSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Sharps Compliance Corp. (NASDAQ: SMED) (“Sharps” or the “Company”), a leading full-service national…

POINT Biopharma Confirms No Delays to SPLASH Trial Due to Recent Global Lutetium Supply Interruption

2 years ago

POINT’s industry-leading radioisotope supply chain enabled company to avoid delaysINDIANAPOLIS, March 22, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc.…

CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update on March 29

2 years ago

BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

Palisade Bio (Nasdaq: PALI) Receives FDA “Study May Proceed” Letter for Pivotal Phase 3 Clinical Trial Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery

2 years ago

CARLSBAD, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies…